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Abstract
There are several different modalities, e.g., surgery, chemotherapy, and radiotherapy, that are cur-
rently used to treat cancer. It is common practice to use a combination of these modalities to maximize
clinical outcomes, which are often measured by a balance between maximizing tumor damage and min-
imizing normal tissue side effects due to treatment. However, multi-modality treatment policies are
mostly empirical in current practice, and are therefore subject to individual clinicians’ experiences and
intuition. We present a novel formulation of optimal multi-modality cancer management using a finite-
horizon Markov decision process approach. Specifically, at each decision epoch, the clinician chooses an
optimal treatment modality based on the patient’s observed state, which we define as a combination
of tumor progression and normal tissue side effect. Treatment modalities are categorized as (1) Type
1, which has a high risk and high reward, but is restricted in the frequency of administration during a
treatment course, (2) Type 2, which has a lower risk and lower reward than Type 1, but may be repeated
without restriction, and (3) Type 3, no treatment (surveillance), which has the possibility of reducing
normal tissue side effect at the risk of worsening tumor progression. Numerical simulations using various
intuitive, concave reward functions show the structural insights of optimal policies and demonstrate the
potential applications of using a rigorous approach to optimizing multi-modality cancer management.
1 Introduction
Cancer accounts for nearly 1 in every 7 deaths worldwide, claiming more lives than HIV/AIDS, tuber-
culosis, and malaria combined [1]. It has been projected that by 2030 the global burden of cancer will
grow to 21.7 million new cancer cases and 13 million cancer deaths worldwide due to growing and aging
populations, with more increases expected due to the adoption of behaviors and lifestyles associated
with economic development and urbanization [1], a trend already observed in economically transitioning
countries [2]. In the United states, cancer is the second leading cause of death, accounting for nearly 1
in every 4 deaths. It is the leading cause of death in 21 states and among adults aged 40 to 79 [3].
There are several different modalities that are currently used to treat cancer, including surgery,
chemotherapy, radiotherapy, hormone therapy, immune therapy, and targeted therapy [1, 2]. Most pa-
tients receive treatment using two or more modalities, often sequentially, in the course of managing their
cancer. As noted in [4], “cancer treatments using a single therapeutic agent often result in limited clinical
outcomes due to tumor heterogeneity and drug resistance. Combination therapies using multiple modal-
ities can synergistically elevate anti-cancer activity while lowering doses of each agent, hence, reducing
side effects.” Some examples include combining gene therapy and chemotherapy with nanotechnology [4];
using surgery, chemotherapy, and radiotherapy for head and neck cancers [5], combining immunotherapy
with the more traditional surgery, radiotherapy, chemotherapy, and targeted therapy [6]; treating glioblas-
tomas with a combination of surgery, radiotherapy, and systemic therapy [7]; treating brain metastases
using a combination of surgery, radiotherapy, and symptomatic care [8]; treating localized rectal cancer
using a combination of surgery, chemotherapy, radiotherapy, and adjuvant cytotoxic therapy [9]; and
chemoradiotherapy plus surgery for esophageal cancer [10].
Unfortunately, multi-modality treatment decisions in current practice rely predominantly on individ-
ual clinician’s experiences, and therefore the optimality of such decisions is unclear. Considering that
there are many treatment options available to us in modern medicine and numerous possible outcomes
associated with each treatment course, counting on intuition or a heuristic search for optimal multi-
modality treatment policies can be costly and inefficient [11, 12]. There have been limited efforts to
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model optimal multi-modality treatments using a mathematical approach. For example, in [13] Beil
and Wein studied the optimal sequencing of surgery, chemotherapy, and radiotherapy, using ordinary
differential equations to describe the behavior of the primary tumor and metastases. They suggested
two novel treatment sequences from their study, but the weakness of their model is the requirement of
an accurate, a priori knowledge of the 14 parameters used in the equations. Alternatively, Hathout et
al. investigated the optimal combination of radiotherapy and surgery in the treatment of glioblastoma
patients using a reaction-diffusion partial differential equation to simulate the diffusion and proliferation
of the tumor and radiation cell-kills [14]. Their model provides answers to when the extent of surgical
resection, in combination with radiotherapy, adds survival benefits.
The purpose of this paper is to propose a novel mathematical framework to optimize multi-modality
treatment policies for cancer management using a finite-horizon Markov decision process (MDP) ap-
proach, and to demonstrate the feasibility and potential of the proposed model. An MDP with a finite
planning horizon is a mathematical framework for optimizing a sequence of actions in a stochastic system,
where the state of the system is given at the beginning of each decision epoch. The goal is to maximize
the expected reward at the end of the planning horizon. MDPs have been used to model problems in
various industries, e.g., robotics [15, 16] and economics [17, 18], and more recently have been success-
fully applied to problems in medicine. For example, MDPs have been used to find optimal treatments
for sperocytosis [19] and ischemic heart disease [20], to determine the optimal dose in several radiation
treatment periods [21], and to decide whether to accept or reject an offered kidney or living-donor liver
for transplantation [11, 22, 23]. A combination of MDPs and dynamic decision networks has been used to
develop a general-purpose artificial intelligence framework that can “think like a doctor” for personalized
medicine, increasing patient outcomes and decreasing costs [12]. In our model, we define the system state
as a combination of the degree of tumor progression (or tumor control) and normal tissue side effect. The
action space consists of three different categories of treatment modalities based on the characteristics of
repeatability, tumor reduction, and risk to normal tissue. At each decision epoch the clinician observes
the patient’s state and chooses an optimal treatment modality accordingly to maximize the expected
terminal reward, which is a function of the patient’s final state.
The rest of this paper is organized as follows. In Section 2 we introduce our model formulation with
details on treatment planner’s actions (treatment modalities), patient states, state transition probabilities
and boundary conditions, and reward functions, where we review the backward induction method to
obtain optimal policies. In Section 3 we present numerical simulations using various intuitive reward
functions to show the structural insights of optimal policies and the potential benefits of using a rigorous
model for optimal multi-modality cancer management. Specifically, we demonstrate that changes in the
reward functions and state transition probabilities result in changes of the optimal policy that correspond
with clinical intuition. Finally, we conclude our paper and discuss possible future extensions to our model
in Section 4.
2 Problem formulation
Consider a treatment course with T periods, where a patient seeks an optimal treatment decision. We
define the four components of our MDP model: the treatment planner’s actions in Section 2.1, the patient
state in Section 2.2, state transition probabilities in Section 2.3, and the intermediate and terminal reward
functions in Section 2.4. Finally, we present the backward induction algorithm to solve the recursive
Bellman equations in Section 2.5.
2.1 Treatment planner’s actions
We denote the action space as A = {M1,M2,M3}, where M1,M2, and M3 represent the Type 1, 2, and
3 modalities respectively. The definition of each modality type is as follows:
• Type 1: Treatment modalities with a high risk (increasing side effect) and high reward (decreasing
tumor progression). The frequency of administering Type 1 modalities is restricted.
• Type 2: Treatment modalities with a lower risk and lower reward than Type 1. May be repeated
without restriction in frequency.
• Type 3: No treatment (surveillance). Has a higher probability of reducing normal tissue side effect
and increasing tumor progression than the Type 1 and Type 2 modalities. May be repeated without
restriction in frequency.
2
We categorize treatment modalities into three types acknowledging that certain modalities may be
more effective but limited in the frequency of their administration. For example, whole brain radiotherapy
to manage brain metastases is only done once during a patient’s lifetime due to the normal tissue side
effect associated with it, whereas the gamma knife or partial brain external beam radiotherapy can be
administered multiple times until normal tissue toxicity has reached its tolerance level [24]. For such
cases, whole brain therapy is categorized as Type 1 while gamma knife and external beam radiotherapy
are categorized as Type 2 modalities.
In general, M1 and M2 may each represent a set of modalities, but to simplify notation we consider
the case where there is only one modality of each type in this section. We consider a case with two
modalities of Type 2 in Section 3.5. Similarly, we restrict the Type 1 modality (M1) to one-time use
during the course of treatment to simplify notation, though this is certainly not a requirement of our
model.
2.2 Patient state
Let the total number of possible states for normal tissue side effect and tumor progression be m + 1
and n + 1 respectively. Let st = (ht, φt, τt) ∈ S denote the patient state in treatment period t with
t = 1, 2, . . . , T . Each state variable is defined as follows:
• ht ∈ H = {0, 1}: History of Type 1 modality in period t such that ht = 1 if the Type 1 modality
has been used in periods 1, 2, . . . , or t− 1. Otherwise ht = 0.
• φt ∈ Φ = {0, 1, . . . ,m}: Normal tissue side effect due to treatment observed in period t. Φ is
ordered such that φt = 0 represents no side effect while φt = m represents the worst possible side
effect (patient death due to normal tissue side effect).
• τt ∈ T = {0, 1, . . . , n}: Tumor progression observed in period t. T is ordered such that τt = 0
represents the best patient state (tumor remission) and τt = n represents the worst possible patient
state (patient death due to tumor progression).
We denote the full patient state space by the Cartesian product S = (H × Φ× T ).
2.3 State transition probabilities
When treatment modality at ∈ A is implemented in period t for a patient in state st, the patient’s state
in period t+1 is assumed to be st+1 with the probability of Pt(st+1|st, at). We assume that the transition
probabilities for each state variable are conditionally independent of one another, that is,
Pt(st+1|st, at) = PHt (ht+1|ht, at)× PΦt (φt+1|φt, at)× P Tt (τt+1|τt, at). (1)
This assumption is in line with our intuition that tumor progression and normal tissue side effects do
not depend on each other but depend on the treatment type only. The classification of M1 as having a
higher risk and higher reward than M2 can then be written in terms of state transition probabilities as
follows:
Higher risk in side effects: PΦt (φt+1|φt,M1) ≥ PΦt (φt+1|φt,M2) for φt+1 > φt (2)
Higher reward in tumor control: P Tt (τt+1|τt,M1) ≥ P Tt (τt+1|τt,M2) for τt+1 < τt (3)
We define the transition probabilities for the history variable, ht, deterministically to restrict the
number of administrations of M1 during the course of treatment as follows:
PHt (1|ht,M1) = 1 for all ht ∈ H, (4)
PHt (ht|ht, at) = 1 for at ∈ {M2,M3}. (5)
The restriction that Type 1 modalities may only be used once during the course of treatment is imposed
through the transition probabilities in the following manner:
Pt(1,m, n|1, φt, τt,M1) = 1 for all φt ∈ Φ and τt ∈ T . (6)
This means that the patient will transition to the worst possible state, i.e., st+1 = (1,m, n), if M1 is
chosen when the history of M1 use is positive.
We impose absorbing boundary conditions to simulate either the death of the patient (when side
effect or tumor progression reaches their maximum value) or tumor remission (when tumor progression
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reaches zero). We note that in the remission state only tumor progression is fixed, allowing side effect to
improve in subsequent treatment periods.
Death due to side effect: Pt(ht,m, τt|ht,m, τt, at) = 1 for all at ∈ A (7)
Death due to tumor progression: Pt(ht, φt, n|ht, φt, n, at) = 1 for all at ∈ A (8)
Tumor remission: P Tt (0|0, at) = 1 for all at ∈ A (9)
2.4 Reward functions
We denote the real-valued terminal reward function rT+1(s), which quantifies the patient’s utility of
being in state s at the end of their treatment course, t = T + 1. After each treatment period the patient
may also receive an intermediate reward, rt(st, at, st+1), which is associated with an action chosen in
period t, such as the cost of using treatment at and the expected outcome in the patient’s next state,
st+1. While our model will work with any reward function, in general patient utility corresponding to
better states should be at least as large as patient utility corresponding to worse states. This means that
r(φ, τ) ≥ r(φ′, τ) for φ ≤ φ′, (10)
r(φ, τ) ≥ r(φ, τ ′) for τ ≤ τ ′, (11)
because states are ordered such that smaller states represent better patient conditions. Some commonly
used utility measures in medicine are the quality-adjusted life year, the disability-adjusted life year, and
the healthy-years equivalent [25, 26, 27, 28].
2.5 Bellman equations and backward induction
For each patient state st ∈ S and treatment period t ∈ {1, 2, . . . , T}, our goal is to maximize the ex-
pected patient utility at the end of the treatment course, that is, E
[∑T
t=1 rt(st, at, st+1) + rT+1(sT+1)
]
.
Bellman’s recursive equations to solve this problem is given by
Vt(s) =
∑
s′∈S
Pt(s
′|s, a)
(
rt(s, a, s
′) + Vt+1(s
′)
)
for t = 1, 2, . . .¸ , T (12)
with boundary condition VT+1(s) = rT+1(s). The optimal policy can be solved recursively for all st ∈ S
and t = 1, 2, . . . , T with the well-known backward induction algorithm [29]:
Set VT+1(s) = rT+1(s) for all s ∈ S
for t = T, T − 1, . . . , 1 do
Vt(s) = max
a∈A
∑
s′∈S
Pt(s
′|s, a)
(
rt(s, a, s
′) + Vt+1(s
′)
)
at(s) = arg max
a∈A
∑
s′∈S
Pt(s
′|s, a)
(
rt(s, a, s
′) + Vt+1(s
′)
)
end for
With increasing dimensions in the state space S and the action space A, the problem faces the “curses
of dimensionality” and may be solved using approximate dynamic programming [30].
3 Numerical simulations
In this section we present numerical simulations to illustrate the structure of optimal multi-modality
treatment policies generated with our MDP model. In Section 3.1 we present a base case of the state
transition probabilities and reward functions used in our simulations, including the general assumptions
made to make them clinically relevant. Next, in Sections 3.2 and 3.3 we explore how changes in the
terminal and intermediate reward functions affect the optimal policies. The effect of changes in transition
probabilities on the optimal policies is presented in Section 3.4. Finally, we explore a scenario with
multiple Type 2 treatment modalities in Section 3.5. We note that the general assumptions made
in this section are specific to our numerical simulations and not necessary for solving optimal multi-
modality treatment policies using our model. In practice, transition probabilities can be estimated from
correlations between treatment modalities and patient outcomes from the clinical literature, which is
beyond the scope of this paper.
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3.1 Base case
We define a base case with one modality of each type, where A = {M1,M2,M3}, without intermediate
rewards, letting rt = 0 for t = 1, 2, . . . , T . In all of our numerical simulations, we use 11 states for φ and
τ , i.e., m = n = 10, and three treatment periods, that is, T = 3. First, in Section 3.1.1 we specify our
assumptions used to assign state transition probabilities, and we introduce our reward functions derived
from clinical intuition and practice in Section 3.1.2. This is followed by the optimal policies resulted
from these base transition probabilities and rewards in Section 3.1.3.
3.1.1 State transition probabilities
For our numerical simulations, we utilize stationary transition probabilities that depend only upon the
changes between states rather than on the actual value of the state. This means that
Pt(st+1|st, at) = P (st+1|st, at) for t = 1, 2, . . . , T, (13)
PΦ(φt+1|φt, at) = PΦ(φ′t+1|φ′t, at) whenever φt+1 − φt = φ′t+1 − φ′t, and (14)
P T (τt+1|τt, at) = P T (τ ′t+1|τ ′t , at) whenever τt+1 − τt = τ ′t+1 − τ ′t . (15)
For simplicity, we assume that state variables can only change by one increment between two successive
treatment periods, and that tumor progression only improves after treatment (M1 or M2) while side effect
only improves after surveillance (M3). Therefore, tumor progression can either stay the same or get better
(decrease by one) between two successive treatment periods after M1 or M2 is chosen, while side effect
can either stay the same or get worse (increase by one). This implies that
P T (0|0, at) = 1 and PΦ(m|m,at) = 1 for at ∈ {M1,M2}, (16)
which is consistent with our absorbing boundary conditions. When M3 (surveillance) is chosen, tumor
progression can either stay the same or get worse between two successive treatment periods, while side
effect can either stay the same or get better. This implies that
P T (n|n,M3) = 1 and PΦ(0|0,M3) = 1. (17)
For our numerical simulations, we use the state transition probabilities for non-boundary states
defined in Table 1. The transition probabilities for the history variable h is as defined in Equation (5).
Modality
Side Effect in period t+ 1 Tumor Progression in period t+ 1
(at)
(φt+1) (τt+1)
φt − 1 φt φt + 1 τt − 1 τt τt + 1
M1 0 0.4 0.6 0.7 0.3 0
M2 0 0.6 0.4 0.6 0.4 0
M3 0.6 0.4 0 0 0.3 0.7
Table 1: State transition probabilities PΦ(φt+1|φt, at) and PT (τt+1|τt, at) used in the base case.
3.1.2 Reward functions
The reward (patient utility) of being in state s depends on the patient’s side effect (φ) and tumor
progression (τ). We define our patient utility using additively separable reward functions, where f
measures the utility of the normal tissue side effect being in state φ, and g measures the utility of tumor
progression being in state τ . Let dφ and dτ be the parameters associated with functions f and g. Then
the total reward is defined as
r(φ, τ) = cφf(φ; dφ) + cτg(τ ; dτ ), (18)
where cφ and cτ are the weighting factors of f and g, which represent the relative importance of the side
effect and tumor progression respectively.
We use concave reward functions for f and g, where improvements made in worse patient states are
more appreciated than improvements made in healthier states. These relationships can often be found
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in studies that examine patient utility as a function of clinical states [31, 32, 33, 34]. Thus, the functions
f and g can be written as
Side effect: f(φ; dφ) =
100
mdφ
(
mdφ − φdφ
)
, (19)
Tumor progression: g(τ ; dτ ) =
100
ndτ
(
ndτ − τdτ
)
, (20)
where dφ ≥ 1 and dτ ≥ 1 to make f and g concave. Note that dφ = dτ = 1 indicates a linear function.
The functions f and g are normalized to 100 so that the reward ranges between 0 (minimum) and 100
(maximum). We note that the concave shape of the reward function is not necessary to our model, but
is utilized in our examples to simulate clinically relevant scenarios as previously demonstrated in [21].
Finally, we use a stationary intermediate reward function that does not depend on the action, i.e.,
rt(st, at, st+1) = r(st, st+1) for t = 1, 2, . . . , T . For the base case, we use dφ = dτ = 2 and cφ = cτ = 1/2
in the terminal reward function (rT+1), without intermediate reward functions, that is, r(st, st+1) = 0
for t = 1, 2, . . . , T .
3.1.3 Numerical results of the base case
Figure 1 shows the optimal policy for the base case with transition probabilities from Table 1 and rewards
functions described in Section 3.1.2. The terminal reward function is shown on the left of the figure,
where the contours show the isolines of the reward for each given state defined with tumor progression
on the horizontal axis and normal tissue side effect on the vertical axis. With lighter regions denoting
larger rewards, we see that the lower left corner is the patient’s best state, i.e. zero side effect and
tumor remission, while the upper right corner is the patient’s worst state, i.e. maximum side effect and
tumor progression. On the right of the figure, the optimal policy is shown for states defined with tumor
progression on the horizontal axis and normal tissue side effect on the vertical axis. The top row shows
the optimal policy when the Type 1 modality has never been used, i.e. h = 0, and the bottom row shows
the optimal policy for h = 1. Each column represents a distinctive treatment period.
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Figure 1: (Left) Quadratic terminal reward function, rT+1(φ, τ) =
1
2
f(φ; 2) + 1
2
g(τ ; 2). (Right) Optimal treatment
policy for T = 3 and A = {M1,M2,M3} with transition probabilities given in Table 1.
The results agree with clinical intuition that, in general, when the patient’s normal tissue side effect
is more detrimental to their overall health than their tumor progression, i.e., the patient has severe side
effects but their tumor progression is less concerning (upper left corner), the optimal action is surveillance
(M3). On the other hand, when the patient’s current state is on the lower right corner, that is, severe
tumor progression with minimal side effects, the optimal action is to use more aggressive treatment
modalities (M1 if it has not been used). At the absorption states φ = m or τ = n, there is no difference
among modalities when M1 has not been used. However, since using M1 when h = 1 deterministically
brings the patient’s next state to the worst possible state, the optimal policy with h = 1 does not
include M1 for any states or treatment periods except for the worst state, st = (1,m, n). We note that
with h = 0 the Type 1 modality tends to be saved for later treatment periods, so M2 is used more in
the beginning of the treatment course. This observation will be compared with the case in Section 3.3
when an intermediate reward is added, where the patient’s state during intermediate treatment periods
contributes to the total reward, unlike the base case where the total reward depends only on the patient’s
final state.
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3.2 Effect of terminal reward function shapes on optimal policy
In this section we demonstrate how changes in the terminal reward function affect optimal policies.
Specifically, we consider various shapes of the terminal reward function in Section 3.2.1 and the relative
importance of side effect and tumor progression in the terminal reward function in Section 3.2.2.
3.2.1 Shape of terminal reward functions
We examine how the shape of the terminal reward function, represented by the exponents dφ and dτ ,
affects the optimal policy when side effect and tumor progression are weighted equally, that is, cφ = cτ =
1/2. We use the same exponent for f and g, letting dφ = dτ ≡ d. Therefore, we compare the optimal
policies generated using the following terminal reward function:
rT+1(φ, τ) =
1
2
f(φ, d) +
1
2
g(τ, d) (21)
=
50
10d
{
(10d − φd) + (10d − τd)
}
, (22)
where d ∈ {3/2, 2(base case), 3}. (23)
The exponent d = 1 corresponds to a linear function, where the reward of decreasing tumor progression
or side effect is identical in all patient states. When d > 1, the reward received from decreasing tumor
progression or side effect in worse patient states is larger than the reward received in better states. As
d increases, the reward at each patient state also increases, except at the best and worst states where
rewards are fixed at zero and 100. This in turn results in a steeper slope and faster transition from “bad”
states to “good” states. The optimal policies resulting from d = 3/2 and d = 3 are shown in Figure 2
and Figure 3 respectively, which can be compared with the base case in Figure 1.
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Figure 2: (Left) Terminal reward function rT+1(φ, τ) =
1
2
f(φ; 3/2)+ 1
2
g(τ ; 3/2). (Right) Optimal treatment policy
for T = 3 and A = {M1,M2,M3} with base transition probabilities given in Table 1.
As d gets closer to unity, the reward function becomes linear, so improvements made in any patient
state (better or worse) are rewarded the same way. Therefore, Figure 2 with d = 3/2 shows that
the optimal policy in the upper left corner (high side effect) and the lower right corner (worse tumor
progression) is more like the rest of the states as compared to the base case. As we increase the exponent
d, the improvements made near the worst patient states (the worst tumor progression or worst side
effect) are rewarded higher than the improvements made in other states. This produces treatments that
prioritize getting the patient out of these states, with both more surveillance in states with high side
effect (upper left corner) and more of the M1 modality in states with worse tumor progression (lower
right corner). The optimal policy with d = 3 is shown in Figure 3. For the remainder of our numerical
simulations, we use quadratic terminal reward functions, letting d = 2, in order to compare with the base
case.
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Figure 3: (Left) Cubic terminal reward function, rT+1(φ, τ) =
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f(φ; 3) + 1
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g(τ ; 3). (Right) Optimal treatment
policy for T = 3 and A = {M1,M2,M3} with base transition probabilities given in Table 1.
3.2.2 Relative importance of side effect and tumor progression
Next we look at the effect of the relative importance of side effect and tumor progression in the concave
terminal reward function with cφ = c and cτ = (1− c), given by
rT+1(φ, τ) = cf(φ; 2) + (1− c)g(τ ; 2) (24)
= c
(
100− φ2
)
+ (1− c) (100− τ2) , (25)
where c ∈ {1/3, 1/2(base case), 2/3}. The optimal policies with c = 1/3 and 2/3 are shown in Figure 4
and Figure 5 respectively.
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Figure 4: (Left) Quadratic terminal reward function rT+1(φ, τ) =
1
3
f(φ; 2) + 2
3
g(τ ; 2). (Right) Optimal treatment
policy for T = 3 and A = {M1,M2,M3} with transition probabilities given in Table 1.
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Figure 5: (Left) Quadratic terminal reward function rT+1(φ, τ) =
2
3
f(φ; 2) + 1
3
g(τ ; 2). (Right) Optimal treatment
policy for T = 3 and A = {M1,M2,M3} with transition probabilities given in Table 1.
As we weight tumor progression more heavily than side effect in the terminal reward function, the
optimal policies become more aggressive. Specifically, decreasing c produces policies that recommend
treatment over surveillance in more states with an increased frequency of using M1 when h = 0 and M2
when h = 1.
3.3 Effect of intermediate rewards on optimal policies
In this section we explore the effect of adding an intermediate reward function on the optimal policies.
We consider two cases, where we collect rewards for (1) reducing side effect during the treatment course
by adding rφ, and (2) reducing tumor progression during the treatment course by adding rτ . Using
quadratic rewards (dφ = dτ = 2), the intermediate reward functions rφ and rτ are defined as
rφ(st, st+1) = cmf(φt+1; 2), t = 1, 2, . . . , T, (26)
rτ (st, st+1) = cmg(τt+1; 2), t = 1, 2, . . . , T, (27)
where we let cm = 1/4.
The optimal policies using rφ and rτ are presented in Figure 6 and Figure 7 respectively.
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Figure 6: Optimal treatment policy for T = 3 and A = {M1,M2,M3} with transition probabilities given in Table
1, terminal reward function rT+1(φ, τ) =
1
2
f(φ; 2) + 1
2
g(τ ; 2), and intermediate reward function rφ(φ) =
1
4
f(φ; 2).
The optimal policy using rφ tends to select actions that reduce side effect during the treatment course;
therefore, the optimal policy has a higher proportion of surveillance (M3) and a lower proportion of M1
and M2 with h = 0, and M2 with h = 1 in all treatment periods compared to the base case in Figure 1.
We note that M1, which can only be used once, is saved for the last treatment period (t = T ) when rφ is
used. This can be compared with Figure 5, where the importance of reducing side effect is larger in the
terminal reward than the importance of reducing tumor progression. When cφ is larger than cτ without
intermediate rewards, the optimal policy still includes M1 for certain states in earlier treatment periods.
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Figure 7: Optimal treatment policy for T = 3 and A = {M1,M2,M3} with transition probabilities given in Table
1, terminal reward function rT+1(φ, τ) =
1
2
f(φ; 2) + 1
2
g(τ ; 2), and intermediate reward function rτ (τ) =
1
4
g(τ ; 2).
On the other hand, the optimal policy using rτ tends to select actions that reduce tumor progression
during the treatment course. In this case, the proportion of M3 decreases in all treatment periods and
the proportion of M1 and M2 with h = 0, and M2 with h = 1 increases. Therefore the preference for
treatment over surveillance is higher. We note the difference in the optimal policy resulting from adding
rτ to that of Figure 4, where cτ is increased in the terminal reward. The proportion of M1, which can
only be used once, is higher in all treatment periods when rτ is used. This is different from using a larger
cτ than cφ in the terminal reward function, where M1 is used in a larger portion of the states in the last
treatment period than in the earlier periods.
3.4 Effect of transition probabilities on optimal policies
In this section we show how changes in transition probabilities affect the optimal treatment policy. First,
we explore a case where the treatment modality M1 is more effective in reducing tumor progression
than in the base case, where we increase the probability that the tumor progression will decrease after
treatment, that is,
P T (τt − 1|τt,M1) = 0.8 and P T (τt|τt,M1) = 0.2. (28)
Modality
Side Effect in period t+ 1 Tumor Progression in period t+ 1
(at)
(φt+1) (τt+1)
φt − 1 φt φt + 1 τt − 1 τt τt + 1
M1 0 0.4 0.6 0.8 0.2 0
M2 0 0.6 0.4 0.6 0.4 0
M3 0.6 0.4 0 0 0.3 0.7
Table 2: State transition probabilities PΦ(φt+1|φt, at) and PT (τt+1|τt, at) with the assumption that M1 is more
effective than the base case in reducing tumor progression.
The optimal policy computed using the transition probabilities in Table 2 is shown in Figure 8. It
shows a more aggressive treatment policy that uses M1 in a higher proportion of the states compared
to the base case. We note an interesting effect of the boundary condition at τ = 0, specifically, M1 is
chosen for several states where τ = 1 and φ < 4 (without severe side effect) at t = 1 due to the fact that
tumor remission in earlier treatment periods (t = 1, 2) is now more likely if M1 is chosen.
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Figure 8: Optimal treatment policy for T = 3 and A = {M1,M2,M3} with transition probabilities given in Table
2, modified to make M1 more effective than the base case in decreasing tumor progression, and quadratic terminal
reward function rT+1(φ, τ) =
1
2
f(φ, 2) + 1
2
g(τ, 2).
Next we explore a case where the treatment modality M2 is less risky than that in the base case in
terms of increasing side effect, where we decrease the probability that the side effect will increase after
treatment, that is,
PΦ(φt|φt,M2) = 0.7 and PΦ(φt + 1|φt,M2) = 0.3. (29)
The state transition probabilities in this case are shown in Table 3 and the resulting optimal policy
is shown in Figure 9. We see that this change makes M2 more favorable and produces an optimal policy
that uses M2 in a higher proportion of the states in all treatment periods.
Modality
Side Effect in period t+ 1 Tumor Progression in period t+ 1
(at)
(φt+1) (τt+1)
φt − 1 φt φt + 1 τt − 1 τt τt + 1
M1 0 0.4 0.6 0.7 0.3 0
M2 0 0.7 0.3 0.6 0.4 0
M3 0.6 0.4 0 0 0.3 0.7
Table 3: State transition probabilities PΦ(φt+1|φt, at) and PT (τt+1|τt, at) with the assumption that M2 is less
risky than the base case in terms of increasing side effect.
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Figure 9: Optimal treatment policy for T = 3 and A = {M1,M2,M3} with transition probabilities given in Table 3,
modified to make M2 less risky than the base case in increasing side effect, and quadratic terminal reward function
rT+1(φ, τ) =
1
2
f(φ, 2) + 1
2
g(τ, 2).
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Finally, we investigate a case where the surveillance modality M3 is less likely to increase tumor
progression than the base case, where we change probabilities in the fourth row of Table 1 to
P T (τt|τt,M3) = 0.7 and P T (τt + 1|τt,M3) = 0.3. (30)
The state transition probabilities in this case are shown in Table 4 and the resulting optimal policy is
shown in Figure 10. We see an increase in the amount of surveillance suggested by the policy in all
treatment periods. We also note that M3 is optimal in more states with higher side effects compared
to the base case. This policy may be appropriate in the case of a slowly growing tumor, where the
probability of increasing tumor progression by surveillance is relatively low for a given treatment time
period.
Modality
Side Effect in period t+ 1 Tumor Progression in period t+ 1
(at)
(φt+1) (τt+1)
φt − 1 φt φt + 1 τt − 1 τt τt + 1
M1 0 0.4 0.6 0.7 0.3 0
M2 0 0.6 0.4 0.6 0.4 0
M3 0.6 0.4 0 0 0.7 0.3
Table 4: State transition probabilities PΦ(φt+1|φt, at) and PT (τt+1|τt, at) with the assumption that M2 is less
risky than the base case in terms of increasing side effect.
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Figure 10: Optimal treatment policy for T = 3 and A = {M1,M2,M3} with transition probabilities given in Table
4, modified to make M3 less risky than the base case in increasing tumor progression, and quadratic terminal
reward function rT+1(φ, τ) =
1
2
f(φ, 2) + 1
2
g(τ, 2).
3.5 Multiple Type 2 modalities
In this section we demonstrate our model with multiple modalities of a particular treatment type. Specif-
ically, we consider a case where there are two modalities of Type 2, i.e., A = {M1,M2a,M2b,M3}. We
order the index of the treatment modalities based on effectiveness, that is,
PΦ(φt+1|φt,M1) ≥ PΦ(φt+1|φt,M2a) ≥ PΦ(φt+1|φt,M2b) ≥ PΦ(φt+1|φt,M3) for φt+1 > φt, (31)
P T (τt+1|τt,M1) ≥ P T (τt+1|τt,M2a) ≥ P T (τt+1|τt,M2b) ≥ P T (τt+1|τt,M3) for τt+1 < τt. (32)
The transition probabilities used in this case are presented in Table 5, and the resulting optimal policy
is shown in Figure 11. The trend is qualitatively similar to the previous cases with three modalities. We
note that there are only ties between consecutive treatment modalities, for example, M1 never ties with
M2b or M3, because of the ordering in the action space.
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Modality
Side Effect in period t+ 1 Tumor Progression in period t+ 1
(at)
(φt+1) (τt+1)
φt − 1 φt φt + 1 τt − 1 τt τt + 1
M1 0 0.4 0.6 0.7 0.3 0
M2a 0 0.5 0.5 0.6 0.4 0
M2b 0 0.6 0.4 0.5 0.5 0
M3 0.6 0.4 0 0 0.3 0.7
Table 5: State transition probabilities PΦ(φt+1|φt, a) and PT (τt+1|τt, a) used for a case with T = 3 and
A = {M1,M2a,M3a,M4}
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Figure 11: Optimal treatment policy for T = 3 and A = {M1,M2a,M2b,M3} with probabilities given in Table 5
and quadratic terminal reward function rT+1(φ, τ) =
1
2
f(φ; 2) + 1
2
g(τ ; 2).
4 Conclusions and future research
With diverse patient characteristics, numerous treatment modalities available in modern medicine, and
various possible outcomes, making treatment decisions tailored to each individual patient is extremely
complex. It may no longer be practical to make optimal decisions based solely on individual clinician’s
experiences and empirical intuition. We proposed a novel mathematical framework to model optimal
treatment policies for cancer therapy using a finite-horizon Markov decision process (MDP). Numeri-
cal simulations using simplified patient states and clinically intuitive reward functions have shown the
potential application of our model to aid in treatment decision-making. Using state transition probabil-
ities obtained from treatment-outcome clinical data, our model can assist clinicians in making optimal
decisions for the patient’s current state. Our model has the potential to be personalized to individual
patients via custom utility functions based on the patient’s own preferences, with the addition of state
variables such as age, specific side effects of interests, and tumor types. It can also serve as a tool to
explain an expected treatment course to patients.
As we take more realistic and detailed attributes into consideration in the model, the problem becomes
computationally intractable due to increased state and outcome space. We leave these high dimensional
problems, which require an approximate dynamic programming approach, for future work. Other po-
tential formulations for future investigation include infinite-horizon MDPs leading to stationary optimal
solutions. An infinite horizon formulation is particularly useful when the patient’s expected treatment
course is unpredictable.
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